State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital of Medicine School, Zhejiang University, Hangzhou 310003, China; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital of Medicine School, Zhejiang University, Hangzhou 310003, China.
Int J Antimicrob Agents. 2018 Jun;51(6):822-828. doi: 10.1016/j.ijantimicag.2018.01.004. Epub 2018 Jan 12.
Global dissemination of the mobile colistin resistance mcr-1 is of particular concern as colistin is one of the last-resort antibiotics for the treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria. In this study, an inactive form of mcr-1 in a fluoroquinolone-resistant and colistin-susceptible uropathogenic Escherichia coli isolate (ECO3347) was characterised. The mcr-1 gene was deactivated by insertion of a 1.7-kb IS1294b element flanked by two tetramers (GTTC) and located on a 62-kb pHNSHP45-like plasmid (p3347-mcr-1). Single-step and multistep selections were used to induce colistin resistance in vitro in ECO3347. ECO3347 acquired colistin resistance (MIC = 16-32 mg/L) only after a serial passage selection with increasing concentrations of colistin (2-8 mg/L). Deactivated mcr-1 was re-activated by loss of IS1294b without any remnants in most colistin-resistant mutants. In addition, a novel amino acid variant (Leu105Pro) in the CheY homologous receiver domain of PmrA was detected in one colistin-resistant mutant. Plasmid p3347-mcr-1 carrying the re-activated mcr-1 gene is transferrable to E. coli J53 recipient with a high conjugation rate (ca. 10 cells per recipient cell). Transconjugants showed an identical growth status to J53, suggesting lack of a fitness cost after acquiring p3347-mcr-1. These results highlight that the disrupted mcr-1 gene has the potential for wide silent dissemination with the help of pHNSHP45-like epidemic plasmids. Inducible colistin resistance may likely compromise the success of clinical treatment and infection control. Continuous monitoring of mcr-1 is imperative for understanding and tackling its dissemination in different forms.
mcr-1 基因的全球传播尤其令人担忧,因为黏菌素是治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染的最后一道防线抗生素之一。在本研究中,我们对一株氟喹诺酮耐药但黏菌素敏感的尿路致病性大肠杆菌(ECO3347)中的 mcr-1 失活形式进行了表征。mcr-1 基因被一个 1.7kb 的 IS1294b 元件插入失活,该元件两侧是两个四聚体(GTTC),位于一个 62kb 的 pHNSHP45 样质粒(p3347-mcr-1)上。我们使用一步法和多步法选择在体外诱导 ECO3347 对黏菌素产生耐药性。只有在经过一系列带有递增黏菌素浓度(2-8mg/L)的传代选择后,ECO3347 才获得黏菌素耐药性(MIC=16-32mg/L)。在大多数耐黏菌素突变体中,失活的 mcr-1 是通过失去 IS1294b 而重新激活的,而没有任何残留。此外,在一个耐黏菌素突变体中还检测到 PmrA 的 CheY 同源受体结构域中的一个新的氨基酸变异(Leu105Pro)。携带重新激活的 mcr-1 基因的质粒 p3347-mcr-1 可以通过高接合率(约每受体细胞 10 个细胞)转移到 E. coli J53 受体中。转导子与 J53 表现出相同的生长状态,表明在获得 p3347-mcr-1 后没有适应度成本。这些结果表明,在 pHNSHP45 样流行质粒的帮助下,失活的 mcr-1 基因具有广泛传播的潜力。诱导性黏菌素耐药性可能会严重影响临床治疗和感染控制的效果。对 mcr-1 的持续监测对于理解和应对其不同形式的传播至关重要。